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Abstract
Background: Recent evidence suggests that acetate-buffered infusions result in better hemodynamic stabilization
than 0.9% saline in patients undergoing major surgery. The choice of buffer in balanced crystalloid solutions may
modify their hemodynamic effects. We therefore compared the inopressor requirements of Ringer’s acetate and
lactate for perioperative fluid management in patients undergoing cardiac surgery.
Methods: Using a randomized controlled double-blind design, we compared Ringer’s acetate (RA) to Ringer’s lactate
(RL) with respect to the average rate of inopressor administered until postoperative hemodynamic stabilization was
achieved. Secondary outcomes were the cumulative dose of inopressors, the duration of inopressor administration, the
total fluid volume administered, and the changes in acid-base homeostasis. Patients undergoing elective valvular
cardiac surgery were included. Patients with severe cardiac, renal, or liver disease were excluded from the study.
Results: Seventy-five patients were randomly allocated to the RA arm, 73 to the RL. The hemodynamic profiles
were comparable between the groups. The groups did not differ with respect to the average rate of inopressors
(RA 2.1 mcg/kg/h, IQR 0.5–8.1 vs. RL 1.7 mcg/kg/h, IQR 0.7–8.2, p = 0.989). Cumulative doses of inopressors and
time on individual and combined inopressors did not differ between the groups. No differences were found in
acid-base parameters and their evolution over time.
Conclusion: In this study, hemodynamic profiles of patients receiving Ringer’s lactate and Ringer’s acetate were
comparable, and the evolution of acid-base parameters was similar. These study findings should be evaluated in
larger, multi-center studies.
Trial registration: Clinicaltrials.gov NCT02895659. Registered 16 September 2016.
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Introduction
Cardiovascular surgery generates a systemic inflamma-
tory response that increases oxygen consumption and is
associated with changes in cardiac output and oxygen
delivery [1, 2]. Perioperative hemodynamic support is
influenced by the patients’ underlying cardiac disease,
the complexity of the surgical intervention, the inflam-
matory response to extracorporeal circulation, and the
need for perioperative anticoagulation [3]. Patients often
require several hours of postoperative hemodynamic sup-
port after cardiac surgery while still sedated and intubated
on the intensive care unit (ICU) [4, 5], and frequently,
they receive a substantial amount of intravenous fluid
within a short time period.
Volume replacement strategies and type of fluid used in
patients undergoing cardiac surgery have changed over
the years [6]. Safety concerns regarding the use of syn-
thetic colloid solutions in cardiac surgery patients [2, 7, 8]
have led to increased use of crystalloid infusions [6, 9, 10].
Recently, two studies suggested that acetate-buffered
crystalloid solutions result in better hemodynamic
stabilization than 0.9% saline in patients undergoing
major surgical procedures [11, 12]. However, the use of
acetate-containing balance solutions has been criticized
due to the risk of vasodilatation and metabolic alkalosis
[13–18]. Patients undergoing cardiac surgery typically
require several hours of hemodynamic support, and both
acetate-buffered and lactate-buffered crystalloids are
used in clinical practice.
We therefore hypothesized that the use of an acetate-
based balanced crystalloid solution for perioperative
fluid replacement in patients undergoing cardiac surgery
would result in a lower average rate of inopressors, a
lower cumulative dose of inopressors, a shorter total
time on inopressors, and a lesser amount of fluid needed




We conducted a randomized double-blind single-center
clinical trial investigating the effect of Ringer’s acetate
(RA) vs. Ringer’s lactate (RL) on hemodynamic sta-
bility and fluid requirements in patients undergoing
cardiac surgery.
Ethical considerations
The study was approved by the ethics committee of the
Canton of Bern (2016-01039) and was registered in a
clinical trial register (NCT02895659). Written preopera-
tive informed consent was obtained from every patient
included in the study.
Setting
The study was conducted between December 1, 2016,
and October 19, 2017, in the Department of Intensive
Care Medicine of the Inselspital, Bern University
Hospital, University of Bern, Bern, Switzerland.
Study endpoints
The primary endpoint of this study was the average rate of
inopressors (norepinephrine and epinephrine) per kilo-
gram body weight-hour until hemodynamic stabilization.
Secondary study endpoints were (i) cumulative inopressor
dose, (ii) time on inopressors, (iii) cumulative dose of and
time on inodilators and vasodilators, (iv) total amount of
fluid administered until hemodynamic stabilization, and
(v) occurrence of metabolic alkalosis. The study groups
were compared with regard to the average rate of inopres-
sor administration, the average rate of norepinephrine and
epinephrine administration, the cumulative inopressor
dose, the cumulative time on inopressors, the cumulative
dose of and time on inodilators and vasodilators, the
total amount of fluid administered until hemodynamic
stabilization, and the occurrence of metabolic alkalosis.
Further, fluid balance, urinary output, and blood loss
were defined as outcomes post hoc. Additionally,
patient characteristics and postoperative complications
were evaluated. Metabolic alkalosis was defined as pH
> 7.45 and bicarbonate > 26 mmol/L. Alkalemia was
defined as pH > 7.45.
Time to hemodynamic stabilization: definition of the
study period
We aimed to investigate the perioperative period until
achievement of hemodynamic stabilization. The study
period commenced with the induction of general
anesthesia and ended when hemodynamic stabilization
was achieved. This point in clinical recovery was de-
fined in the following way: (a) successful extubation
and free from vasoactive support; (b) intubated with
inopressor agents, but inopressor dose either weaned
entirely or unchanged for > 8 h or (c) 72 h after ICU
admission. Thereafter, follow-up continued for sec-
ondary endpoints for the duration of the hospital stay.
The study fluid was not restarted once the initial
stabilization was achieved.
The following is the rationale for this definition: the
typical hemodynamic problems after cardiac surgery
include reduced intravascular blood volume accompanied
by peripheral vasoconstriction, low cardiac output (with
or without hypotension) due to compromised cardiac
function, and/or preload, and major changes in vascular
tone [19, 20]. All these may be augmented due to
heart-lung interactions during weaning and due to acute
hemodynamic changes related to extubation. Our clinical
guidelines recommend extubation as soon as the patient is
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awake and hemodynamically stable. Extubation is usually
postponed if the patient needs frequent adjustment of
vasoactive drugs and or volume substitution. We therefore
took “successful extubation and free from vasoactive
drugs” to imply hemodynamic stability and considered
patients who remained intubated without hemodynamic
support or did not need any change in the hemodynamic
management for > 8 h as stable.
Patients
A CONSORT flow chart is provided in Fig. 1.
Patients were eligible for the study if they were
scheduled to undergo an elective open surgical single-
or double-valve procedure, combined valve and cor-
onary bypass surgery, or combined valve and proximal
aortic surgery.
We included routine cardiac surgery patients with no
severe comorbidities. Thus, the exclusion criteria were
as follows: age less than 18 or older than 80 years,
pre-existing severely impaired cardiac or renal function
(EF < 30%; eGFR < 30 mL/min/1.73 m2), pre-existing
anemia necessitating a cardiopulmonary bypass (CPB)
circuit prime with red cell concentrate, chronic inflam-
matory diseases, on long-term steroid medication,
chronic liver disease (bilirubin > 3mg.dl−1), active infec-
tion or sepsis, emergency or redo surgery, planned use
of minimal extracorporeal circuits (MECC) or of early
(in the OR) extubation protocols, and patients with
restrictions to full therapy. Isolated CABG surgery was
excluded since minimized extracorporeal circulation
and a fast-track regimen are used in our center for this
type of cardiac surgery. This results in considerably less
exposure to the intervention (crystalloid load) than the
use of conventional CPB as in valve surgery.
Randomization and material
Computerized randomization was performed in blocks
of 20 patients. Concealment used the opaque sealed
envelope method. After informed consent was obtained,
patients were randomly allocated to receive either RA
(Fresenius Kabi®, Switzerland GmbH; theoretical osmo-
larity 291 mosml/kg, containing sodium 137mmol/L,
potassium 4.0 mmol/L, chloride 110 mmol/L, calcium
1.65 mmol/L, magnesium 1.25 mmol/L, acetate 36.8
mmol/L) or RL (Fresenius Kabi®, Switzerland GmbH;
theoretical osmolarity 278 mosm/L, sodium 130.9
mmol/L, potassium 5.4mmol/L, chloride 111.7mmol/L,
calcium 1.84mmol/L, lactate 28.3mmol/L). For each pa-
tient, a box with concealed bags of study infusion solution
was prepared by a study nurse not involved in the study
or patient care and was handed over to both the
anesthesiologist and the perfusionist prior to the start
of anesthesia. Postoperatively, the box accompanied the
patient to the ICU for further study fluid administra-
tion until hemodynamic stabilization.
Study conduct
All patients underwent monitoring of oxygen saturation,
heart rate, invasive arterial blood pressure, electrocardiog-
raphy, respiratory gas analysis, temperature, urine output,
central venous pressure, intraoperative transesophageal
echocardiography, processed EEG, and postoperative per-
ipheral temperature according to institutional routine.
Maintenance of anesthesia, hemodynamic and perfusion
management, surgical procedures, and cardiopulmonary
bypass weaning were performed according to the de-
partmental standard operating procedures (SOP). All
patients were transferred sedated and ventilated from
the OR to the ICU.
Hemodynamic management
Patients received either RL or RA for intravenous fluid re-
suscitation according to their group allocation. The cardio-
pulmonary bypass circuit was also exclusively primed with
the allocated study fluid. No colloid solutions were used.
Hemodynamic and fluid management was guided by TEE
and dynamic assessment of both fluid responsiveness and
filling pressures, with staged escalation towards vasoactive
and/or inotropic and/or mechanical support in case of per-
sistent low cardiac output (mean arterial pressure (MAP)
< 60mmHg, CCI < 2.2 L/min/m2, SmvO2 < 65%, and/or lac-
tate levels > 2.4mmol/L). The choice of specific agents and
interventions was left to the discretion of the attending
physician specialists.
Following ICU admission, hemodynamic management
[21] was guided using the following targets: MAP 60–90
mmHg, CVP target < 12mmHg, oxygen saturation >
96%, and heart rate 60–110/min. Further, normalization
of peripheral temperature, diuresis (target > 0.5 mL/
kgBW/h), and arterial blood lactate concentration < 2.0
mmol/L were expected as the response to treatment.
During mechanical ventilation, the pCO2 was kept at <
40mmHg. Since patients after cardiac surgery are vaso-
constricted, intravenous fluids were given to restore
intravascular volume during vasodilation, to normalize
peripheral perfusion, and to allow weaning from vaso-
pressors. If patients were not responding as expected,
echocardiography, pulmonary artery catheterization, or
both were used to determine the underlying cause. The
diagnosis and treatment of specific hemodynamic prob-
lems was at the discretion of the intensivist in charge of
the patient.
Statistical analysis
The statistical analysis was performed with Stata® 13.1
(StataCorp, College Station, TX, USA). All randomized
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patients who received the study fluid were included in
the analysis according to a modified intention-to-treat
approach [22]. Normal distribution of continuous va-
riables was tested with the Shapiro-Wilk test. Normally
distributed variables are presented with mean and
standard deviation. Skewed and ordinal variables are
presented as medians with interquartile ranges (IQR).
Normally distributed interval and ordinal variables
were compared using the unpaired t test and skewed
variables using the Wilcoxon rank sum test. Compari-
sons of categorical variables were performed using the
chi-square test or Fisher’s exact test, as appropriate
[23].
The procedure for analyzing the potential baseline
differences between the groups in case of a significant
group effect was log-linear regression analysis. All base-
line characteristics with a p value of < 0.1 were included.
In addition, further confounders related to increased
inopressor use such as aortic insufficiency were also
forced into the model. For the purpose of this analysis,
skewed outcomes were log-transformed; thus, the expo-
nentiated coefficients correspond to the geometric mean
ratio of the outcome.
A mixed restricted cubic spline model was used for
the evaluation of changes in hemodynamics and in acid-
base homeostasis, i.e., mean arterial pressure, peripheral
temperature, urinary output, base access, pH, potassium,
and lactate over time between the study groups. Missing
values were imputed with the use of the last observation
carried forward method for measurements made
after baseline.
p values less than 0.05 were considered statistically
significant. Figures were drawn using Stata®.
Results
Out of 357 screened patients, 150 gave consent and
were randomized, and 148 patients actually received
the study intervention (see Fig. 1). Seventy-five pa-
tients were randomized to the RA group and 73 pa-
tients to the RL group. Patients’ characteristics are
given in Table 1. In the RL group, more patients
underwent a composite graft operation (n = 16, 21.9%
vs. n = 4, 5.3%), whereas in the RA group, more pa-
tients received a single-valve replacement (n = 59, 78.7%
vs. n = 48, 65.8%). The number of patients undergoing
Fig. 1 CONSORT flowchart
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hypothermic cardiac arrest was also higher in the RL
group (p = 0.004). The evolution of blood pressure, per-
ipheral temperature, and urinary output was similar in the
Ringer’s acetate and the Ringer’s lactate groups (Fig. 2).
Primary and secondary study endpoints with respect
to the vasoactive medication are given in Additional file 1
and Table 2.
Patients in the RA group did not differ from the
RL group with respect to the average rate of inopres-
sors (2.1 mcg/kg/h, IQR 0.5–8.1 and 1.7 mcg/kg/h,
IQR 0.7–8.2, respectively, p = 0.989). In the log-linear
regression model adjusted for the baseline differences
between the groups, no significant group effect was
found with respect to the primary outcome (p =
0.494). Data on fluids is presented in Table 2. Fluid
balance, urinary output, and blood loss did not differ
significantly between the groups (data not shown).
Changes in acid-base status over time are shown in
Fig. 3. No difference in the occurrence of metabolic
acidosis (p = 0.327) or alkalemia (p = 0.681) was noted
between the groups. Postoperative outcomes are given in
Table 3. Except for the occurrence of postoperative
Table 1 Patient demographics
Characteristics Total (n = 148) Ringer’s acetate (n = 75) Ringer’s lactate (n = 73) p value*
Sex, n (%)
Male 112 (75.7) 56 (74.7) 56 (76.7) 0.772
Female 36 (24.3) 19 (25.3) 17 (23.3)
Age [years], med (IQR) 67.5 (58.0–72.5) 66.0 (58.0–72.0) 68.0 (59.0–73.0) 0.631
ASA PS [class], n (%) 1.000
3 3 (2.0) 2 (2.7) 1 (1.4)
4 145 (98.0) 73 (97.3) 72 (98.6)
Euroscore, med (IQR) 18 (17–19) 18 (17–19) 18 (16–19) 0.542
SAPS, med (IQR) 54 (44–62) 54 (46–62) 54 (42–62) 0.945
NYHA [grade], n (%) 0.167
0 11 (7.5) 5 (6.8) 6 (8.2)
1 34 (23.1) 18 (24.3) 16 (21.9)
2 69 (46.9) 34 (46.0) 35 (48.0)
3 28 (19.1) 17 (23.0) 11 (15.1)
4 5 (3.4) 0 (0.0) 5 (6.9)
Preoperative ejection fraction [%], med (IQR) 60 (55–65) 60 (55–65) 60 (55–65) 0.795
Preoperative eGFR [mL/min], med (IQR) 70 (53–85) 73 (51–87) 67 (54–83) 0.507
Type of surgery, n (%)
Composite graft (+valve#) 20 (13.5) 4 (5.3) 16 (21.9) 0.004
Other 128 (86.5) 71 (94.7) 57 (78.1)
Single valve 107 (72.3) 59 (78.7) 48 (65.8)
Single valve + CABG 12 (8.1) 5 (6.7) 7 (9.6
Double valve 6 (4.1) 4 (5.3) 2 (2.7)
Double valve + CABG 1 (0.7) 1 (1.3) 0 (0.0
Triple valve 2 (1.4) 2 (2.7) 0 (0.0)
Duration anesthesia [min], med (IQR) 310 (266–362) 305 (266–353) 310 (264–364) 0.937
Duration surgery [min], med (IQR) 202 (170–251) 205 (176–251) 192 (170–264) 0.812
Aortic cross clamp time [min], med (IQR) 70 (56–90) 67 (53–86) 73 (58–97) 0.172
Hypothermic circulatory arrest n (%) 17 (11.56) 3 (4.00) 14 (19.18) 0.004
Red blood cell transfusions [mL]°, med (IQR) 340 (220–550) 333 (223–575) 350 (174–550) 0.788
Time until initial hemodynamic stabilization [h], med (IQR) 12.06 (9.7–13.9) 12.08 (10.0–13.4) 12.05 (9.1–14.1) 0.649
*Wilcoxon rank sum test for continuous variables and chi-square test
°Fisher’s exact test for categorical variables between the Ringer’s acetate and the Ringer’s lactate study groups including autologous retransfusion and red
cell concentrates
#One patient in the Ringer’s lactate group
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arrhythmia (p = 0.008), no significant differences in postop-
erative outcomes were noted (p all > 0.05).
Sensitivity analysis: inopressors—norepinephrine and
epinephrine
All patients received norepinephrine infusions (n =
148, 100%), and 41 patients (27.7%) received epineph-
rine infusions at some time during the perioperative
period (both p > 0.05 between the groups). The aver-
age norepinephrine rate did not differ between the
RA group (median 4.1 mcg/kg/h, IQR 1.1–11.7) and
the RL group (median 3.4 mcg/kg/h, IQR 1.5–9.5, p
= 0.907). However, patients in the RL group received
significantly more epinephrine on average compared
to the RA group (4.5 μg/kg/h, IQR 0.4–33.0 vs.
0.2 μg/kg/h, IQR 0.1–9.3, p = 0.047). The significant
group effect with regard to the average rate of
epinephrine was persistent when using log-linear
regression analysis controlled for composite graft
operations, deep hypothermic circulatory arrest, and
valvular regurgitation (geometric mean ratio 9.9, 95%
CI 1.3, 78.3, p = 0.030).
If only the period in the ICU is considered, more
patients in the Ringer’s lactate group received epinephrine
infusions (14 [19.2%] vs. 6 [8.0%], p = 0.047).
Discussion
The main finding of this study is that acetate-buffered
balanced Ringer’s solution does not differ significantly
from lactate-buffered Ringer’s solution with respect to
postoperative hemodynamic stability and phamacological
support with inotropic agents in patients scheduled for
elective cardiac valve surgery. Also, we observed no
difference in the cumulative amount of perioperative i.v.
fluids necessary or in acid-base profiles. A small but
significant increased average rate of epinephrine was
noted in the group with lactate-buffered infusion. The
difference in rate was very small, however, and likely of
no clinical importance.
Previous observations in humans suggested that the
choice of crystalloid fluid might influence the require-
ments for perioperative vasoactive agents [11, 12, 24]. In
these studies, the use of 0.9% saline was significantly
associated with more frequent vasoactive medication
when compared to an acetate-buffered infusion group.
Fig. 2 Hemodynamic profile for the Ringer’s acetate and the Ringer’s lactate group
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This led to the hypothesis that either the high chloride
load of 0.9% saline or the potentially beneficial effects of
acetate on the cardiovascular system, seen in the animal
model, may be responsible for the difference seen in
these studies [12]. Therefore, we designed the current
study comparing two chloride-reduced infusion solu-
tions, one of which is acetate-buffered.
Based on our results, we now reject our hypothesis that
acetate-buffered Ringer’s solution is superior to Ringer’s lactate
solution with respect to perioperative hemodynamic stability.
The hemodynamic effects of acetate are controversial.
Some studies have reported a decline in blood pressure
after sodium acetate infusion [25–28], whereas others
observed stable [29, 30] or even increasing blood pres-
sure [16]. However, most of this evidence originates from
the investigations of either sodium acetate infusion or
acetate-buffered dialysis, where the acetate load is much
higher than in fluid replacement with acetate-buffered
Ringer’s solution. Therefore, such findings are not
generalizable to populations receiving perioperative
fluid therapy with acetate-buffered infusions [31]. In
fact, the few existing animal and human studies investi-
gating acetate-buffered crystalloid infusions noted poten-
tially beneficial effects on cardiac function [14, 16, 32].
In our study, the hemodynamic profiles of patient
groups receiving either RA or RL did not differ sig-
nificantly, even though large quantities of i.v. fluid were
administered. RA therefore appears to be a feasible alter-
native to RL for fluid resuscitation in the critically ill in
terms of hemodynamic effects.
The lack of difference between the two study arms with
respect to hemodynamic stabilization in comparison with
earlier trials might also be attributed to the reduced chlo-
ride load of buffered infusions when compared to saline.
Chloride excess was linked to adverse hemodynamic
outcomes in several previous human and experimental
studies [33–36]. However, the data suggesting that the use
of 0.9% saline leads to hemodynamic effects are limited
Table 2 Primary and secondary endpoints—vasoactive medication
Primary endpoint Ringer’s acetate (n = 75),
median (IQR)




Average rate of inopressors (norepinephrine and epinephrine) [μg/kg/h] until
hemodynamic stabilization
2.1 (0.5–8.1) 1.7 (0.7–8.2) 0. 989
Secondary endpoints—vasoactive medication
Average rate of norepinephrine [μg/kg/h] until hemodynamic stabilization 1.8 (0.5–6.7) 1.5 (0.6–4.7) 0.672
Average rate of epinephrine [μg/kg/h]§ per hour on epinephrine 0.2 (0.1–9.3) 4.5 (0.4–33.0) 0.047
Average rate of inopressors (norepinephrine and epinephrine)
[μg/kg/h] per hour on inopressors
4.1 (1.0–11.8) 3.7 (1.6–12.1) 0.959
Average rate of norepinephrine [μg/kg/h]# per hour on norepinephrine 4.1 (1.1–11.7) 3.4 (1.5–9.5) 0.907
Average rate of epinephrine [μg/kg/h]§ per hour on epinephrine 0.2 (0.1–9.3) 4.5 (0.4–33.0) 0.047
Cumulative dose of inopressors [μg/kg] 22 (5–83) 20 (7–114) 0.928
Cumulative dose of norepinephrine [μg/kg] 19 (5–71) 16 (6–61) 0.726
Cumulative dose of epinephrine [μg/kg] 22 (5–83) 20 (7–114) 0.928
Time on inopressors [h]° 4.8 (4.1–10.7) 6.1 (4.0–10.6) 0.505
Time on norepinephrine [h]#° 4.8 (4.1–6.4) 4.5 (3.7–7.4) 0.836
Time on epinephrine [h]*° 0.0 (0.0–0.0) 0.0 (0.0–3.4) 0.209
Cumulative dose of inodilators, ICU [μg] 0 (0.0–0.0) 0 (0.0–0.0) 0.375
Time on inodilators, ICU [min] 0 (0.0–0.0) 0 (0.0–0.0) 0.386
Cumulative dose of vasodilators [mg] 0 (0.0–2.8) 0 (0.0–4.2) 0.844
Time on vasodilators, ICU [h] 0 (0.0–1.7) 0 (0.0–6.4) 0.726
Secondary endpoints—fluids
Total amount of study fluid received (mL) 6677 (5325–8479) 6104 (4769–7855) 0.272
Total amount of fluid received other than study fluid during study period (mL) 0 (0–0) 0 (0–0) 0.976
Total amount of fluid received after initial hemodynamic stabilization until ICU
discharge (mL)
289 (104–972) 255 (121–631) 0.711
Total amount of fluid received from the start of anesthesia to ICU discharge (mL) 7189 (5622–9120) 6644 (5400–8379) 0.234
*Not including four patients who received one single-bolus injection of epinephrine only
#Not including one patient who received one single-bolus injection of norepinephrine only
°From intubation to end of study period defined
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and certainly need to be verified in a larger cohort
before any definitive conclusions can be drawn.
Acetate and lactate are both weak acids that are con-
verted into bicarbonate [31]. Lactate can be utilized by
multiple pathways and is unlikely to produce acute changes
in acid-base balance [37]. In contrast, acetate-buffered
solutions may produce metabolic alkalosis due to rapid
production of bicarbonate from acetate [13, 15, 38, 39].
However, a recent systematic review of studies com-
paring acetate-buffered solution to other crystalloids
found that major increases in bicarbonate with acetate-
buffered solutions were rarely observed [31]. Our
study shows that even in patients undergoing cardiac
surgery who receive large quantities of intravenous
fluid within a short time period, the use of an
acetate-buffered infusion solution did not result in a
difference in metabolic alkalosis or alkalemia between
the study groups.
Postoperative arrhythmias were recorded significantly
more often in patients in the RL group than in patients in
the RA group. Electrolyte blood concentrations were simi-
lar. Potential explanations are the differences in case mix,
more frequent use of epinephrine in the RL group, and/or
pre-existing but not documented differences in atrial
geometry; however, this needs to be investigated further.
In our study cohort, 7.4% of the patients suffered from
new postoperative neurological deficit. Cardiac valve pro-
cedures per se are a known risk factor for postoperative
neurologic deficits in patients undergoing cardiac surgery
[40]. In addition, the high proportion of patients that re-
ceived an aortic or composite-graft procedure, the advanced
age, and the high incidence of perioperative arrhythmia, all
of which are well-known risk factors for perioperative
strokes, might explain the proportion of 6.1% in our study
population suffered from postoperative new stroke [40, 41].
The results of this study show that RA appears to be a
feasible alternative to RL for perioperative fluid resusci-
tation in the critically ill, even when large quantities are
needed. This could have implications for clinical practice.
The limitations of our study are its single-center design
and the exclusion of patients with more severe cardiac and
renal impairment. The former were excluded due to the
higher need for perioperative inopressors in this population
as a result of the underlying cardiac disease; that latter were
excluded because patients with severe kidney dysfunction
have an impaired ability to react to changes in acid-base
homeostasis. Another limitation might arise from the
fact that patients only received the study fluid until
hemodynamic stabilization and not until ICU discharge.
However, in our ICU, we give maintenance fluid after
Fig. 3 Acid-base homeostasis—profile of Ringer’s acetate and Ringer’s lactate
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hemodynamic stabilization/extubation mainly for potassium
substitution to prevent arrhythmia, and the amount is gener-
ally negligible. Further limitations arise from the imbalanced
distribution of ascending aortic procedures between the
groups, from the exclusion of patients undergoing only iso-
lated CABG surgery, and due to the limited sample size. In
addition, our study was designed as a pragmatic trial com-
paring the two solutions in the context of both groups re-
ceiving usual care. We cannot address the possible specific
hemodynamic effects (e.g., vasodilatation) of either solution.
Further confirmatory studies are certainly warranted
in the future.
Conclusion
In this study, in patients undergoing cardiac valve surgery,
hemodynamic profiles and inopressor requirements were
similar in patients receiving Ringer’s lactate and Ringer’s
acetate for perioperative fluid resuscitation. Between-
group differences in metabolic alkalosis commonly asso-
ciated with larger loads of acetate infusion were not
observed in this study. In this trial, Ringer’s acetate solu-
tion appears to be an acceptable alternative to Ringer’s
lactate solution for perioperative fluid resuscitation in car-
diac surgery. Our results need to be verified in a larger
cohort, however.
Additional file
Additional file 1: Table S1. Primary and secondary
endpoints—anesthesia versus ICU. (DOCX 15 kb)
Abbreviations
ICU: Intensive care unit; MAP: Mean arterial pressure; OR: Operating room;
RA: Ringer’s acetate; RL: Ringer’s lactate; SOP: Standard operating procedures
Table 3 Postoperative outcomes
Characteristics Ringer’s acetate (n = 75) Ringer’s lactate (n = 73) p value*
Occurrence of arrhythmia, n (%) 24 (32.0) 39 (53.4) 0.008
Acute kidney injury, n (%)# 11 (14.7) 10 (13.7) 0.866
Risk 10 8 0.901
Injury 1 1
Failure 0 1
New neurological deficit, med (IQR) 4 (5.3) 7 (9.6) 0.324
Critical illness polyneuropathy 0 1
Ischemic stroke 4 5
Peripheral nerve lesion 0 1
Coronary angiography, n (%) 2 (2.7) 5 (6.9) 0.272
Postoperative drainage output 950 (550–1200) 1000 (560–1320) 0.415
Received blood product transfusion, n (%) 24 (32.0) 19 (26.0) 0.424
Postoperative infection, n (%) 4 (5.3) 3 (4.1) 1.000
Other complications, n (%) 8 (10.7) 4 (5.5) 0.368
Delirium 1 0
Pneumothorax 2 0
Significant pleural effusion 2 1
Skin rash 1 1
Transient hypoxemia 2 2
Surgical re-exploration needed, n (%) 2 (2.7) 6 (8.2) 0.166
Need for postoperative mechanical circulatory support, n (%) 0(0.0) 2 (2.7)+ 0.242
Length of stay [days], med (IQR)
ICU 0.9 (0.7–0.9) 0.9 (0.8–0.9) 0.494
IMC 0.0 (0.0–0.0) 0.0 (0.0–1.0) 0.362
Hospital 9.0 (8.0–12.0) 9.0 (8.0–10.2) 0.425
In-hospital mortality 0 0
#According to the RIFLE criteria
*Wilcoxon rank sum test for continuous and Fisher’s exact test for categorical variables between the Ringer’s acetate and Ringer’s lactate study groups
+One patient arrived with IABP from the OR, and one patient needed veno-arterial ECMO support in ICU
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